Compare
Kairos Pharma, Ltd. vs Vyome Holdings, Inc vs Adial Pharmaceuticals, Inc. vs OS Therapies Inc
| Latest fiscal year | Kairos Pharma, Ltd. KAPA | Vyome Holdings, Inc HIND | Adial Pharmaceuticals, Inc. ADIL | OS Therapies Inc OSTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $319.7K | n/a | n/a |
| Revenue growth (YoY) | n/a | +24.4% | n/a | n/a |
| Gross margin | n/a | 68.4% | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/a |
| Net margin | n/a | n/m | n/a | n/a |
| Net income | -$5.45M | -$10.26M | -$7.98M | -$28.75M |
| EPS (Diluted) | -$0.30 | -$4.86 | -$11.93 | -$0.98 |
| Operating cash flow | -$3.44M | -$3.75M | -$6.49M | -$14.24M |
| Free cash flow | n/a | n/a | n/a | -$14.70M |
| Cash & equivalents | $4.49M | $4.98M | $5.88M | n/a |
| Total assets | $6.54M | $6.50M | $6.67M | $6.84M |
| Total liabilities | n/a | $2.74M | $1.40M | $11.86M |
| Shareholders' equity | $6.34M | $3.76M | $5.28M | -$6.10M |
| Return on year-end equity | -85.9% | -272.8% | -151.2% | n/a |
| Shares outstanding | 20.82M | 5.92M | 1.11M | 37.11M |
Revenue, most recent five fiscal years
| Fiscal year | Kairos Pharma, Ltd. | Vyome Holdings, Inc | Adial Pharmaceuticals, Inc. | OS Therapies Inc |
|---|---|---|---|---|
| Latest | n/a | $319.7K Ended 2025-12-31 | n/a | n/a |
| 1 year earlier | n/a | $256.9K Ended 2024-12-31 | n/a | n/a |
| 2 years earlier | n/a | $8.68M Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | $11.24M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $13.60M Ended 2021-12-31 | n/a | n/a |